Trial Profile
An Open-Label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-Line Treatment of Subjects With Predominantly Non-Squamous Cell Stage IIIBwet/IV Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 02 May 2019 This trial has been completed in France according to European Clinical Trials Database record.
- 08 Oct 2015 Status changed from completed to discontinued according to results published in the Journal of Thoracic Oncology.
- 07 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.